Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 13.13% | 40.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.13% | 40.94% | |||
| Cost of Revenue | 174.19% | 5.09% | |||
| Gross Profit | -150.94% | 116.00% | |||
| SG&A Expenses | -18.46% | 27.83% | |||
| Depreciation & Amortization | 0.00% | -0.17% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 110.42% | 11.63% | |||
| Operating Income | -285.79% | 628.42% | |||
| Income Before Tax | -323.31% | 405.04% | |||
| Income Tax Expenses | 404.10% | 3,113.67% | |||
| Earnings from Continuing Operations | -381.36% | 373.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -381.36% | 373.21% | |||
| EBIT | -285.79% | 628.42% | |||
| EBITDA | -268.71% | 437.89% | |||
| EPS Basic | -378.24% | 368.76% | |||
| Normalized Basic EPS | -277.68% | 649.05% | |||
| EPS Diluted | -385.34% | 375.97% | |||
| Normalized Diluted EPS | -300.18% | 599.78% | |||
| Average Basic Shares Outstanding | 1.12% | 0.94% | |||
| Average Diluted Shares Outstanding | -10.24% | 7.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||